CN110709402A - 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 - Google Patents

杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 Download PDF

Info

Publication number
CN110709402A
CN110709402A CN201880030204.6A CN201880030204A CN110709402A CN 110709402 A CN110709402 A CN 110709402A CN 201880030204 A CN201880030204 A CN 201880030204A CN 110709402 A CN110709402 A CN 110709402A
Authority
CN
China
Prior art keywords
group
heteroaryl
cycloalkyl
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880030204.6A
Other languages
English (en)
Other versions
CN110709402B (zh
Inventor
吕贺军
刘俊
郝旭辉
关东亮
陈磊
白骅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Original Assignee
ZHEJIANG HAIZHENG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHEJIANG HAIZHENG PHARMACEUTICAL CO Ltd filed Critical ZHEJIANG HAIZHENG PHARMACEUTICAL CO Ltd
Publication of CN110709402A publication Critical patent/CN110709402A/zh
Application granted granted Critical
Publication of CN110709402B publication Critical patent/CN110709402B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及式(I)所示的杂芳基并嘧啶酮类衍生物、其制备方法及其作为治疗剂的用途，特别是作为乙酰辅酶A羧化酶(ACC)抑制剂的用途，其中式(I)中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201880030204.6A 2017-06-15 2018-06-12 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 Active CN110709402B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710450023 2017-06-15
CN2017104500236 2017-06-15
PCT/CN2018/090804 WO2018228369A1 (zh) 2017-06-15 2018-06-12 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途

Publications (2)

Publication Number Publication Date
CN110709402A true CN110709402A (zh) 2020-01-17
CN110709402B CN110709402B (zh) 2022-05-10

Family

ID=64659988

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030204.6A Active CN110709402B (zh) 2017-06-15 2018-06-12 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途

Country Status (3)

Country Link
CN (1) CN110709402B (zh)
TW (1) TW201904974A (zh)
WO (1) WO2018228369A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102577824B1 (ko) 2017-01-22 2023-09-13 선샤인 레이크 파르마 컴퍼니 리미티드 티에노피리미딘 유도체 및 의약에서 이의 용도
JP7067725B2 (ja) * 2017-07-17 2022-05-16 ナンジン ルイジエ ファーマテック カンパニー， リミテッド Ａｃｃ阻害剤としての新規な化合物およびそれらの使用
CN110959007B (zh) * 2017-07-26 2022-07-01 南京圣和药业股份有限公司 作为acc抑制剂的化合物及其应用
CN111808077B (zh) * 2019-04-12 2023-05-02 浙江海正药业股份有限公司 哌嗪酰胺衍生物，其制备方法及其在医药上的用途
CN116745299A (zh) * 2021-02-07 2023-09-12 正大天晴药业集团股份有限公司 噻吩并嘧啶衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071169A1 (en) * 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CN104470931A (zh) * 2012-05-21 2015-03-25 拜耳医药股份有限公司 取代的苯并噻吩并嘧啶
US20160229865A1 (en) * 2013-09-18 2016-08-11 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of btk and/or jak3 kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
CN108349995B (zh) * 2015-11-25 2021-08-03 吉利德阿波罗公司 吡唑acc抑制剂及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071169A1 (en) * 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CN104105485A (zh) * 2011-11-11 2014-10-15 尼普斯阿波罗有限公司 Acc抑制剂和其用途
CN104470931A (zh) * 2012-05-21 2015-03-25 拜耳医药股份有限公司 取代的苯并噻吩并嘧啶
US20160229865A1 (en) * 2013-09-18 2016-08-11 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of btk and/or jak3 kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COLUMBUS, OHIO, US REGISTRY[ONLINE]: "STN检索报告", 《STN REGISTRY》 *

Also Published As

Publication number Publication date
WO2018228369A1 (zh) 2018-12-20
TW201904974A (zh) 2019-02-01
CN110709402B (zh) 2022-05-10

Similar Documents

Publication Publication Date Title
CN110709402B (zh) 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途
TWI751163B (zh) Ｆｇｆｒ４抑制劑、其製備方法和應用
JP6898043B2 (ja) ＴｒｋＡ阻害活性を有する含窒素複素環および炭素環誘導体
RU2770437C2 (ru) Конденсированное циклическое производное, обладающее ингибирующей активностью в отношении mgat-2
KR20210003160A (ko) 메틸 변형 효소 조절제, 이의 조성물 및 용도
US10202389B2 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN104718204B (zh) 噁唑烷‑2‑酮‑嘧啶衍生物
AU2013354552B2 (en) Substituted pyridopyrazines as Syk inhibitors
CN110431143B (zh) 杂芳基并嘧啶酮类衍生物及其制备方法和用途
WO2020188467A1 (zh) 作为激酶抑制剂的稠合三环化合物
TW201307344A (zh) 雜芳基並嘧啶類衍生物、其製備方法和用途
WO2017069224A1 (ja) Ｍｇａｔ２阻害活性を有するスピロ環誘導体
CN111196814B (zh) 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
CN110431144B (zh) 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
WO2017110841A1 (ja) Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体
CN111836819A (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
WO2021117759A1 (ja) 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤
CN110650961B (zh) Parp抑制剂、其药物组合物、制备方法和应用
CN105237523B (zh) 嘧啶衍生物及其制备方法、用途
TWI707853B (zh) 1,2-二氫-1,6-萘啶類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途
CN115703760A (zh) 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用
CN117677614A (zh) 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
CN112574253A (zh) 磷酸或磷酸酯类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220329

Address after: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 46

Applicant after: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd.

Applicant after: Shanghai Angrui Pharmaceutical Technology Co., Ltd

Address before: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 46

Applicant before: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant